ATE529429T1 - Tricyclische spiroderivate als crth2-modulatoren - Google Patents

Tricyclische spiroderivate als crth2-modulatoren

Info

Publication number
ATE529429T1
ATE529429T1 AT06763238T AT06763238T ATE529429T1 AT E529429 T1 ATE529429 T1 AT E529429T1 AT 06763238 T AT06763238 T AT 06763238T AT 06763238 T AT06763238 T AT 06763238T AT E529429 T1 ATE529429 T1 AT E529429T1
Authority
AT
Austria
Prior art keywords
spiro derivatives
tricyclic spiro
crth2 modulators
crth2
modulators
Prior art date
Application number
AT06763238T
Other languages
English (en)
Inventor
Matthias Schwarz
Eric Sebille
Christophe Cleva
Cedric Merlot
Dennis Church
Patrick Page
Jacqueline Macritchie
John Atherall
Stefano Crosignani
Doris Pupowicz
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE529429T1 publication Critical patent/ATE529429T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06763238T 2005-05-24 2006-05-23 Tricyclische spiroderivate als crth2-modulatoren ATE529429T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (1)

Publication Number Publication Date
ATE529429T1 true ATE529429T1 (de) 2011-11-15

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06763238T ATE529429T1 (de) 2005-05-24 2006-05-23 Tricyclische spiroderivate als crth2-modulatoren

Country Status (20)

Country Link
US (1) US8236963B2 (de)
EP (1) EP1891075B1 (de)
JP (1) JP5567268B2 (de)
KR (1) KR101333861B1 (de)
CN (1) CN101300259B (de)
AR (1) AR055959A1 (de)
AT (1) ATE529429T1 (de)
AU (1) AU2006251138C1 (de)
BR (1) BRPI0610209A2 (de)
CA (1) CA2602965C (de)
DK (1) DK1891075T3 (de)
ES (1) ES2375614T3 (de)
MX (1) MX2007014256A (de)
NZ (1) NZ562772A (de)
PL (1) PL1891075T3 (de)
PT (1) PT1891075E (de)
RU (1) RU2478639C2 (de)
UA (1) UA90145C2 (de)
WO (1) WO2006125784A1 (de)
ZA (1) ZA200709819B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147588A (en) 2006-08-07 2012-12-31 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
JP2012532915A (ja) 2009-07-15 2012-12-20 メルク セローノ ソシエテ アノニム Ｃｒｔｈ２調節物質としての三環式インドール由来のスピロ誘導体
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
CA2790139C (en) 2010-03-22 2018-03-13 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
CA2817585A1 (en) 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
ES2624808T3 (es) 2011-05-11 2017-07-17 The Regents Of The University Of Michigan Antagonistas de MDM2 espirooxindólicos
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CA2939892C (en) 2014-03-17 2020-03-31 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN106103437A (zh) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
EP3932914A1 (de) 2015-03-13 2022-01-05 Valo Health, Inc. Alpha-cinnamid-verbindungen und zusammensetzungen als hdac8-inhibitoren
ES2733468T3 (es) * 2015-07-15 2019-11-29 Hoffmann La Roche Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato
CN108026093B (zh) 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
SI3484889T1 (sl) 2016-07-18 2020-11-30 F. Hoffmann-La Roche Ag Derivati etinila
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
IE53102B1 (en) 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US5948807A (en) 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
HUP0202248A3 (en) * 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
CA2500083A1 (en) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
CA2563707A1 (en) 2004-04-20 2005-11-03 Pfizer Inc. Method of treating neuropathic pain using a crth2 receptor antagonsit

Also Published As

Publication number Publication date
JP5567268B2 (ja) 2014-08-06
MX2007014256A (es) 2008-03-26
DK1891075T3 (da) 2011-12-19
JP2008542238A (ja) 2008-11-27
ZA200709819B (en) 2009-09-30
NZ562772A (en) 2010-01-29
PL1891075T3 (pl) 2011-12-30
RU2478639C2 (ru) 2013-04-10
EP1891075A1 (de) 2008-02-27
KR101333861B1 (ko) 2013-11-28
PT1891075E (pt) 2011-11-10
US8236963B2 (en) 2012-08-07
AU2006251138B2 (en) 2012-08-09
KR20080031191A (ko) 2008-04-08
US20090318486A1 (en) 2009-12-24
RU2007147430A (ru) 2009-06-27
EP1891075B1 (de) 2011-10-19
CA2602965A1 (en) 2006-11-30
ES2375614T3 (es) 2012-03-02
AU2006251138A1 (en) 2006-11-30
AU2006251138C1 (en) 2013-08-29
UA90145C2 (ru) 2010-04-12
CA2602965C (en) 2013-12-31
CN101300259A (zh) 2008-11-05
AR055959A1 (es) 2007-09-12
CN101300259B (zh) 2013-08-28
BRPI0610209A2 (pt) 2010-06-01
WO2006125784A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
DK1891075T3 (da) Tricykliske spiroderivater som CRTH2-modulatorer
ATE510831T1 (de) Hydrierte benzoäcüthiophenderivate als immunmodulatoren
DE602007006531D1 (de) Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
ATE486877T1 (de) Azaspiroderivate
ATE532784T1 (de) 3-deazapurinderivate als tlr7-modulatoren
DE602008003116D1 (de) 8-oxychinolinderivate als modulatoren des bradykinin-b2-rezeptors
EP1953165A4 (de) Aza-substituierte spiroderivate
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
DK2069335T3 (da) Pyridin-3-ylderivater som immunomoduleringsmidler
DE602008003015D1 (de) Heterocyclische spiroverbindungen
ATE538091T1 (de) Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
ATE521588T1 (de) Phenyloxy-substituierte phenylamidin-derivate als pestizide
ZA200700684B (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
EP1841794A4 (de) Adam-9-modulatoren
CR10039A (es) Derivados espirocíclicos
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE495161T1 (de) N-benzyl-n'-arylcarbonylpiperazinderivate als lxr-modulatoren
ATE490251T1 (de) Tricyclische opioidmodulatoren
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE469899T1 (de) Spiropiperidinderivate
ATE512137T1 (de) Benzoylpiperidinderivate als doppelmodulatoren des 5-ht2a- und des d3-rezeptors
EP1915162A4 (de) Modulatoren
EP1751115A4 (de) Theramuteinmodulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1891075

Country of ref document: EP